BridgeBio Secures Asia Pacific Distribution for ATTR-CM Drug
BBIO sits 74% above its 52-week low of $38.575.
Summary
BridgeBio Pharma has partnered with DKSH for strategic distribution and commercialization of its transthyretin stabilizer for ATTR-CM in Australia, Singapore, South Korea, and Taiwan. This follows recent positive clinical data and marketing authorization in Brazil for its ATTR-CM drug, Acoramidis. The partnership expands the company's commercial footprint into key Asia Pacific markets, supporting future revenue growth for a significant pipeline asset.
At the time of this announcement, BBIO was trading at $67.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.2B. The 52-week trading range was $38.57 to $84.94. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.